Xencor News
Most Popular Xencor Story
Xencor adds $15M to fifth VC round
Oxford Bioscience Partners and Merlin Nexus joined Novo Nordisk in pumping $15 million more into Xencor's Series E, bringing the grand total to $60 million. Xencor is developing new therapies for... Read more...
Latest Headlines
- February 8, 2008
- October 25, 2007
Paid Research Reports
- RNA therapy: the next big thing after monoclonal antibodies?
- Biotech M&A Strategies: Deal assessments, trends and future prospects
- The Dermatology Market Outlook to 2013: Competitive landscape, pipeline analysis and growth opportunities
- Pipeline Insight: Cancer Overview - Breast, Gynecological, Genitourinary - Diverse drugs approaching the market for many tumor t
- Sales Force Effectiveness
